Canada considers approval of Parkinson’s therapy Crexont
Health Canada will review Knight Therapeutics’ application seeking approval of Crexont, an extended-release formulation of levodopa and carbidopa…
Articles by Andrea Lobo
MJFF funding novel study of anxiety mechanisms in Parkinson’s
A research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support a new study that’s…
FDA approves bilateral ultrasound for Parkinson’s symptoms
The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the…
Target enrollment complete in Phase 1b trial of GT-02287
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s…
Immune T cell response may detect Parkinson’s before symptom onset
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the…
Link between RAB32 mutation, Parkinson’s focus of research grant
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently…
NLRP3 inhibitor found safe, well tolerated in Parkinson’s trial
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to…
Phase 3 trial of prasinezumab in early-stage Parkinson’s planned
Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage…
Rune Labs, Parkinson’s Foundation to study digital biomarkers
Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics…
SLEIPNIR clinical trial platform to test 3 Parkinson’s drugs at once
Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments…